CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Biocytogen Pharmaceuticals Beijng Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Biocytogen Pharmaceuticals Beijng Co Ltd
No. 12
Baocan South Street, Daxing District
Phone: +86 1056967666p:+86 1056967666 Beijing, BEJ  101111  China Ticker: 23152315
Business Summary
Biocytogen Pharmaceuticals Beijing Co Ltd is a China-based company mainly engaged in drug development business and preclinical research. The Company operates its business through five segments. The Gene-editing Services segment provides the customized gene-editing services based on animals as well as cells. The Pre-clinical Pharmacology and Efficacy Evaluation segment provides preclinical pharmacology services for the evaluation of drug efficacy and toxicity. The Animal Models Selling segment breeds and sells the animal models for the external and internal use. The Antibody Development segment utilises its antibody discovery platforms to identify antibodies which have the potential to become drug candidates. The Innovative Drugs Development segment is engaged in research and development of innovative drugs with a focus on oncology and autoimmune disease therapeutics.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023Yes----

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, Chief Executive Officer, General Manager YueleiShen 52 1/1/2021 11/13/2009
Chief Financial Officer BinLiu 53 5/1/2020 5/1/2020
Chief Scientific Officer, Deputy General Manager YiYang 44 12/15/2020 1/1/2020
12 additional Officers and Directors records available in full report.

Business Names
Business Name
2315
I54

General Information
Number of Employees: 1,040 (As of 6/30/2024)
Outstanding Shares: 399,398,420 (As of 6/30/2024)
Stock Exchange: HKG
Fax Number: +86 1056315306


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024